HISUN: Tacrolimus capsules have passed the consistency evaluation of quality and efficacy for generic drugs

HISUN announced that its other tacrolimus capsules have passed the consistency evaluation of generic drug quality and efficacy by the National Medical Products Administration and received the drug supplementary application approval notice. This medication is primarily used to prevent rejection reactions after liver or kidney transplantation, especially when other immunosuppressive drugs cannot be controlled

According to the Zhitong Finance APP, HISUN (600267.SH) announced that it has recently received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration (referred to as "NMPA") for Tacrolimus Capsules. The company's Tacrolimus Capsules have passed the consistency evaluation of quality and efficacy for generic drugs.

Tacrolimus Capsules are mainly used to prevent graft rejection after liver or kidney transplantation. They are used to treat graft rejection that cannot be controlled by other immunosuppressive drugs after liver or kidney transplantation. The original drug Tacrolimus Capsules were developed by Astellas Pharma Co. Limited. Currently, the main domestic manufacturers of Tacrolimus Capsules include Zhejiang HISUN Pharmaceutical Co., Ltd. and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd